Related Experiment Video
Updated: Jun 13, 2026
03:47
A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
Published on: October 25, 2024
Treatment of tuberculosis
1Department of Ambulatory Care & Community Medicine, University of Lausanne, Rue du Bugnon 44, 1011 Lausanne, Switzerland. zellwegerjp@swissonline.ch
Expert Review of Respiratory Medicine
|May 19, 2010
Summary
Tuberculosis treatment relies on potent drug combinations and prolonged, regular therapy to cure patients and prevent transmission and resistance. Challenges include HIV co-infection and rising drug resistance, necessitating new therapeutic strategies.
Area of Science:
- Medicine
- Infectious Diseases
- Public Health
Background:
- Tuberculosis (TB) remains a major global infectious disease, poorly controlled despite decades of available treatments.
- Current TB management adheres to WHO and IUATLD principles: combination therapy, prolonged treatment, and regular dosing to prevent transmission, relapse, and drug resistance.
- Standard treatment involves isoniazid, rifampicin, pyrazinamide, and ethambutol, but challenges like HIV co-infection and drug resistance limit efficacy.
Purpose of the Study:
- To present the rationale behind current World Health Organization (WHO) and International Union Against Tuberculosis and Lung Disease (IUATLD) treatment guidelines for tuberculosis.
- To discuss the management of special circumstances, including drug-resistant tuberculosis and adverse drug events.
- To provide a resource for physicians new to managing tuberculosis.
Main Methods:
- This paper is a review of established tuberculosis treatment principles and guidelines.
- It synthesizes information on standard drug regimens, drug resistance patterns, and management of comorbidities.
- The review focuses on the basis of current international treatment recommendations.
Main Results:
- Standard TB treatment combines isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, followed by isoniazid and rifampicin for 4 months.
- Adverse events from antituberculous drugs are a concern, especially in patients with comorbidities like HIV.
- Increasing drug resistance, particularly in Eastern Europe and Asia, and the high prevalence of HIV co-infection in Africa complicate TB management.
Conclusions:
- Current treatment regimens are effective for most TB cases but face challenges with HIV co-infection and drug resistance.
- New drugs are urgently required to address the growing problem of multidrug-resistant tuberculosis.
- Physicians need comprehensive guidance for managing diverse TB cases, including special situations and adverse events.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:26Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:31Pulmonary Tuberculosis III
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
01:28Pulmonary Tuberculosis II
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:23Tuberculosis
Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...